Renewal of ETAP-Lab’s ISO 9001 certification (v2015)!
Renewal of ETAP-Lab’s ISO 9001 certification (v2015)! A well-managed quality system is key to a high performance, trustworthy preclinical service. ETAP-Lab has been investing in quality management continuously for almost 10 years now. And for 10 years, ISO 9001 certification has recognized the excellence of our quality management system in the areas of consultancy and expertise as well as in the conduct of in vitro and in vivo preclinical research studies. Because we are always scrupulous in carrying out and monitoring our
World Psoriasis Day
Often hidden, psoriasis is a chronic disease affecting more than 125 million patients worldwide. It has a profound impact on quality of life. On this day of solidarity and awareness, ETAP-Lab would like to show its support for psoriasis patients. At ETAP-Lab, we’re already involved in fighting back against psoriasis—our work on developing and providing a translational preclinical research service is driven by our desire to improve quality of life for patients. ETAP-Lab is proud to support the preclinical development of new therapeutics
Meet us at BIOEurope 2021!
ETAP-Lab will be attending BioEurope 25 to 28 October. Our experts Dr. Ahmad Allouche (Head of In Vitro Biology) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory's activities in preclinical Dermatology and Neurology, with Stroke, Alzheimer’s and Parkinson’s diseases. Please feel free to contact us to schedule a video conference. We’re hoping to meet you soon!
The ETAP-Lab poster presented at AAIC is available online
The poster we presented at the Alzheimer’s Association International Conference is now available on the ETAP-Lab website; it’s all about our innovative in vitro and in vivo models of Alzheimer's disease, which are based on the use of human A-Beta 1-42 oligomers. The poster focuses on the main results of the characterisation of the model in the aged mouse. This reproducible and translational model is a new tool for the evaluation of compounds targeting the early stages of Alzheimer's disease. We are
New Alzheimer’s model in the aged mouse: come and meet us at AAIC 2021
ETAP-Lab will present its new Alzheimer's model in the aged mouse at the Alzheimer's Association International Conference, to be held in Denver (USA) from 26 to 30 July 2021. Our expert, Dr. Ahmad Allouche, will be there to answer your questions about our in vitro and in vivo models of Alzheimer's disease, based on the use of human A-Beta 1-42 oligomers. Our poster entitled "New Alzheimer models for drug screening, based on improved human amyloid beta (1-42) oligomer preparations" (number #54152), presents
ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity
Low non-cytotoxic doses of ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity in NETRI’s microfluidic device coupled with MEA. This result is an important milestone towards a more relevant and physiological model of Alzheimer’s disease for drug screening and mechanistic studies. For more information download the Application Note #alzheimer #DrugScreening #microfluidics #neuroscience
Sharing experiences about preclinical models and probiotics!
Did you know that ETAP-Lab has been working in the field of probiotics for more than 15 years, being pioneer in the preclinical study of the gut-brain axis? ETAP-Lab will share its experiences about probiotics testing in preclinical models during the 19th Meet&Match event focused on microbiome, a virtual event scheduled the 1st of July. Dr Jean-François Bisson will talk about: “Assessing beneficial effects of probiotics in small animal models: ETAP-Lab ‘s experience” during Session II at 11h55. This event is co-organized by BioValley France
Bio Digital: Meet us at the World’s Largest Virtual Partnering Experience!
ETAP-Lab will be attending BIODigital as part of the BusinessFrance virtual French pavilion (from 10 to 18 June). Our experts Dr. Jean-François Bisson (VP) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory's activities in preclinical Dermatology, NutritionHealth and Neurology, with Stroke, Alzheimer’s and Parkinson’s diseases. Please feel free to contact us to schedule a video conference. We’re hoping to meet you soon!
Alzheimer’s Disease – a new preclinical model #2
Intracerebral administration of AB1-42 (AβO) oligomers disrupts synaptic function and increases cell death in brain tissue in aged mice. As announced a few weeks ago, we evaluated the effects of AβO on synaptic function and cell survival. Quantification of protein expression in the hippocampus 18 days after intracerebral administration showed disruption to synaptic function (PSD-95) and apoptotic signalling in brain tissue. Figure 1: Graphical representation of PSD-95 expression and Bax/Bcl-2 ratio in the hippocampus, 18 days after AβO
Alzheimer’s Disease – a new preclinical model
As announced a few weeks ago, we tested the effects of donepezil (DPZ) in our Alzheimer's disease model, induced by the administration of beta-amyloid oligomers 1-42. We have shown that memory disorders induced by A-Beta oligomers could be significantly reduced by this symptomatic treatment of Alzheimer's disease. This strengthens the pharmacological validity of our model. In addition, we have once again shown the reproducibility of our model. We have shown that the deleterious effects on memory induced by the administration of A-beta